Tags

Type your tag names separated by a space and hit enter

Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
Int J Clin Pract 2005; 59(7):746-50IJ

Abstract

To assess the efficacy of sibutramine 15 mg once daily as weight reduction in overweight and obese (body mass index > 25 kg/m2) Chinese female type 2 diabetic patients and to evaluate the influence of weight loss on diabetic control, a randomised, double-blind, placebo-control, 12-week study was conducted. Chinese female type 2 diabetic patients, poorly controlled glucose levels and HbA(1C) > 8% were randomly assigned to two groups. In addition to their hypoglycaemic agents (maximal doses of sulphonylureas and metformin), one group (n = 30) received a sibutramine 15 mg once daily for 12 weeks, and the other (n = 30) received placebo for the same period. Comparing the changes that occurred after 12 weeks in the sibutramine and placebo groups, the former showed significantly greater reduction in body weight (2.5 vs. 0.1 kg, p < 0.05), fasting plasma insulin level (28.8 vs. 2.4 pmol/l, p < 0.01), 2-h postprandial blood glucose after standard test meal (3.2 vs. 1.1 mmol/l, p < 0.01), insulin resistance (5.1 vs. 0.2, p < 0.01), HbA1C (1.7% vs. 0.2%, p < 0.05), triglyceride (0.43 vs. 0.12 mmol/l, p < 0.05) and total cholesterol (0.52 vs. 0.08 mmol/l, p < 0.05). No significant differences were found between treatment groups in blood pressure and heart rate. The addition of sibutramine to diet and oral hypoglycaemic therapy resulted in significant weight loss and improvement in metabolic parameters in the treatment group. Sibutramine should be considered for use alongside diet and oral hypoglycaemic therapy in Chinese overweight and obese women with poorly controlled type 2 diabetes.

Authors+Show Affiliations

Division of Endocrinology and Metabolism, Buddhist Tzu-Chi General Hospital and Tzu-Chi University, Hualien, Taiwan, ROC.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15963197

Citation

Wang, T-F, et al. "Effects of Sibutramine in Overweight, Poorly Controlled Chinese Female Type 2 Diabetic Patients: a Randomised, Double-blind, Placebo-controlled Study." International Journal of Clinical Practice, vol. 59, no. 7, 2005, pp. 746-50.
Wang TF, Pei D, Li JC, et al. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2005;59(7):746-50.
Wang, T. F., Pei, D., Li, J. C., Tsai, W. C., Tsai, C. C., Yao, C. Y., ... Kuo, S. W. (2005). Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. International Journal of Clinical Practice, 59(7), pp. 746-50.
Wang TF, et al. Effects of Sibutramine in Overweight, Poorly Controlled Chinese Female Type 2 Diabetic Patients: a Randomised, Double-blind, Placebo-controlled Study. Int J Clin Pract. 2005;59(7):746-50. PubMed PMID: 15963197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. AU - Wang,T-F, AU - Pei,D, AU - Li,J-C, AU - Tsai,W-C, AU - Tsai,C-C, AU - Yao,C-Y, AU - Chang,E-T, AU - Hsieh,M-C, AU - Su,K-Y, AU - Kuo,S-W, PY - 2005/6/21/pubmed PY - 2005/10/4/medline PY - 2005/6/21/entrez SP - 746 EP - 50 JF - International journal of clinical practice JO - Int. J. Clin. Pract. VL - 59 IS - 7 N2 - To assess the efficacy of sibutramine 15 mg once daily as weight reduction in overweight and obese (body mass index > 25 kg/m2) Chinese female type 2 diabetic patients and to evaluate the influence of weight loss on diabetic control, a randomised, double-blind, placebo-control, 12-week study was conducted. Chinese female type 2 diabetic patients, poorly controlled glucose levels and HbA(1C) > 8% were randomly assigned to two groups. In addition to their hypoglycaemic agents (maximal doses of sulphonylureas and metformin), one group (n = 30) received a sibutramine 15 mg once daily for 12 weeks, and the other (n = 30) received placebo for the same period. Comparing the changes that occurred after 12 weeks in the sibutramine and placebo groups, the former showed significantly greater reduction in body weight (2.5 vs. 0.1 kg, p < 0.05), fasting plasma insulin level (28.8 vs. 2.4 pmol/l, p < 0.01), 2-h postprandial blood glucose after standard test meal (3.2 vs. 1.1 mmol/l, p < 0.01), insulin resistance (5.1 vs. 0.2, p < 0.01), HbA1C (1.7% vs. 0.2%, p < 0.05), triglyceride (0.43 vs. 0.12 mmol/l, p < 0.05) and total cholesterol (0.52 vs. 0.08 mmol/l, p < 0.05). No significant differences were found between treatment groups in blood pressure and heart rate. The addition of sibutramine to diet and oral hypoglycaemic therapy resulted in significant weight loss and improvement in metabolic parameters in the treatment group. Sibutramine should be considered for use alongside diet and oral hypoglycaemic therapy in Chinese overweight and obese women with poorly controlled type 2 diabetes. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/15963197/Effects_of_sibutramine_in_overweight_poorly_controlled_Chinese_female_type_2_diabetic_patients:_a_randomised_double_blind_placebo_controlled_study_ L2 - https://doi.org/10.1111/j.1368-5031.2005.00568.x DB - PRIME DP - Unbound Medicine ER -